RNA interference as a potential tool in the treatment of leukaemia

Expert Opinion on Biological Therapy

Volumn 4, Issue 12, 2004, Pages 1921-1929

  Borkhardt, Arndt ^a   Heidenreich, Olaf ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cancer therapy; Delivery; Mechanism; RNA interference; siRNA

Indexed keywords

BCR ABL PROTEIN; DOUBLE STRANDED RNA; FLT3 LIGAND; MESSENGER RNA; NUCLEOTIDE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN P53; SMALL INTERFERING RNA; STAT PROTEIN; TELOMERASE; TRANSCRIPTION FACTOR RUNX1;

CHROMOSOME TRANSLOCATION; FUSION GENE; GENE ACTIVATION; GENE DELIVERY SYSTEM; GENE EXPRESSION SYSTEM; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HALF LIFE TIME; HUMAN; LEUKEMIA; ONCOGENE; REVIEW; RNA CLEAVAGE; RNA INTERFERENCE;

GENE TARGETING; GENE THERAPY; HUMANS; LEUKEMIA; RNA INTERFERENCE; RNA, SMALL INTERFERING;

MAMMALIA;

EID: 10344238542     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.12.1921     Document Type: Review

References (72)

1. ELBASHIR SM, HARBORTH J, LENDECKEL W et al.: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411(6836):494-498.
2. CAPLEN NJ, PARRISH S, IMANI F, FIRE A, MORGAN RA: Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA (2001) 98(17):9742-9747.
3. DYKXHOORN DM, NOVINA CD, SHARP PA: Killing the messenger: short rnas that silence gene expression. Nat. Rev. Mol. Cell. Biol. (2003) 4(6):457-467.
4. SPARKES RS: Cytogenetics of leukemia. N. Engl. J. Med. (1984) 311:848-850.
5. HAGEMEIJER A, VAN DER PLAS DC: Clinical relevance of cytogenetics in acute leukemia. Haematol. Blood Transfus. (1990) 33:23-30.
6. ROWLEY JD: The role of chromosome translocations in leukemogenesis. Semin. Hematol. (1999) 36(4 Suppl. 7):59-72.
7. LUGO TG, PENDERGAST AM, MÅLLER AJ, WITTE ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (1990) 247:1079-1082.
8. GOLDMAN JM, DRUKER BJ: Chronic myeloid leukemia: current treatment options. Blood (2001) 98(7):2039-2042.
9. WILDA M, FUCHS U, WOSSMANN W, BORKHARDT A: Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene (2002) 21(37):5716-5724.
10. SCHERR M, BATTMER K, WINKLER T et al.: Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood (2003) 101(4):1566-1569.
11. MAHON FX, DEININGER MW, SCHULTHEIS B et al.: Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood (2000) 96(3):1070-1079.
12. BARTHE C, CONY-MAKHOUL P, MELO JV, MAHON JR: Roots of clinical resistance to STI-571 cancer therapy. Science (2001) 293(5538):2163.
13. HOCHHAUS A, KREIL S, CORBIN A et al.: Roots of clinical resistance to STI-571 cancer therapy. Science (2001) 293(5538):2163.
14. WOHLBOLD L, VAN DER KUIP H, MIETHING C et al.: Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood (2003) 102(6):2236-2239.
15. CHEN J, WALL NR, KOCHER K et al.: Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. J. Clin. Invest. (2004) 113(12):1784-1791.
16. GOLUB TR, BARKER GF, LOVETT M, GILLILAND DG: Fusion of the PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell (1994) 77:307-316.
17. CIMINO G, RAPANOTTI MC, SPROVIERI T, ELIA L: ALL1 gene alterations in acute leukemia: biological and clinical aspects. Haematologica (1998) 83(4):350-357.
18. GREGORINI A, CINTI C, YOUNG BD: Molecular abnormalities in leukemia: the 11q23 story so far. J. Biol. Regul. Homeost. Agents (1998) 12(4):95-105.
19. PUI CH, BEHM FG, DOWNING JR et al.: 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J. Clin. Oncol. (1994) 12(5):909-915.
20. DIMARTINO JF, CLEARY ML: Mll rearrangements in haematological malignancies: lessons from clinical and biological studies. Br. J. Haematol. (1999) 106(3):614-626.
21. DORDELMANN M, REITER A, BORKHARDT A et al.: Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood (1999) 94(4):1209-1217.
22. PUI CH: Acute lymphoblastic leukemia in children. Curr. Opin. Oncol. (2000) 12(1):3-12.
23. BORKHARDT A, WUCHTER C, VIEHMANN S et al.: Infant acute lymphoblastic leukemia - combined cytogenetic, immunophenotypical and molecular analysis of 77 cases. Leukemia (2002) 16(9):1685-1690.
24. ARMSTRONG SA, STAUNTON JE, SILVERMAN LB et al.: MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. (2002) 30(1):41-47.
25. DEBERNARDI S, LILLINGTON DM, CHAPLIN T et al.: Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. Genes Chromosomes Cancer (2003) 37(2):149-158.
26. DOWNING JR: The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. Br. J. Haematol. (1999) 106(2):296-308.
27. MIYOSHI H, KOZU T, SHIMIZU K et al.: The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. (1993) 12:2715-2721.
28. MULLOY JC, CAMMENGA J, BERGUIDO FJ et al.: Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood (2003) 102(13):4369-4376.
29. BUCHHOLZ F, REFAELI Y, TRUMPP A, BISHOP JM: Inducible chromosomal translocation of AML1 and ETO genes through Cre/toxP-mediated recombination in the mouse. EMBO Rep. (2000) 1(2):133-139.
30. MULLOY JC, CAMMENGA J, MACKENZIE KL et al.: The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood (2002) 99(1):15-23.
31. ASOU H, TASHIRO S, HAMAMOTO K et al.: Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood (1991) 77(9):2031-2036.
32. MATOZAKI S, NAKAGAWA T, KAWAGUCHI R et al.: Establishment of a myeloid leukaemic cell line (SKNO-1) from a patient with t(8;21) who acquired monosomy 17 during disease progression. Br. J. Haematol. (1995) 89(4):805-811.
33. HEIDENREICH O, KRAUTER J, RIEHLE H et al.: AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood (2003) 101(8):3157-3163.
34. MARTINEZ N, DRESCHER B, RIEHLE H et al.: The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells. BMC Cancer (2004) 4(1):44.
35. KOZU T, MIYOSHI H, SHIMIZU K et al.: Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood (1993) 82(4):1270-1276.
36. VOUSDEN KH, LU X: Live or let die: the cell's response to p53. Nat. Rev. Cancer (2002) 2(8):594-604.
37. PELLER S, ROTTER V: TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum. Mutat. (2003) 21(3):277-284.
38. MARTINEZ LA, NAGUIBNEVA I, LEHRMANN H et al.: Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc. Natl. Acad. Sci. USA (2002) 99(23):14849-14854.
39. STERNBERG DW, GILLILAND DG: The role of signal transducer and activator of transcription factors in leukemogenesis. J. Clin. Oncol. (2004) 22(2):361-371.
40. KONNIKOVA L, KOTECKI M, KRUGER MM, COCHRAN BH: Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer (2003) 3(1):23.
41. CHATTERJEE M, STUEHMER T, HERRMANN P et al.: Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood(2004) (In Press).
42. HEIDENREICH O: Oncogene suppression by small interfering RNAs. Curr. Pharm. Biotech. (2004) 5(4):349-354.
43. SCHERR M, MORGAN MA, EDER M: Gene silencing mediated by small interfering RNAs in mammalian cells. Curr. Med. Chem. (2003) 10(3):245-256.
44. RITTER U, DAMM-WELK C, FUCHS U et al.: Design and evaluation of chemically synthesized siRNA targeting the NPM-ALK fusion site in anaplastic large cell lymphoma (ALCL). Oligonucleotides (2003) 13(5):365-373.
45. BRAASCH DA, PAROO Z, CONSTANTINESCU A et al.: Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg. Med. Chem. Lett (2004) 14(5):1139-1143.
46. BRAASCH DA, JENSEN S, LIU Y et al.: RNA interference in mammalian cells by chemically-modified RNA. Biochemistry (2003) 42(26):7967-7975.
47. CZAUDERNA F, FECHTNER M, DAMES S et al.: Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. (2003) 31(11):2705-2716.
48. HAMADA M, OHTSUKA T, KAWAIDA R et al.: Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3′-ends of siRNAs. Antisense Nucleic Acid Drug Dev. (2002) 12(5);301-309.
49. HARBORTH J, ELBASHIR SM, VANDENBURGH K et al.: Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. (2003) 13(2):83-105.
50. SØRENSEN DR, LEIRDAL M, SIOUD M: Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. (2003) 327(4):761-766.
51. LEWIS DL, HAGSTROM JE, LOOMIS AG, WOLFF JA, HERWEIJER H: Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. (2002) 32(1):107-108.
52. SONG E, LEE SK, WANG J et al.: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. (2003) 9(3):347-351.
53. LIU F, SONG Y, LIU D: Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. (1999) 6(7):1258-1266.
54. BOUSSIF O, LEZOUALC'H F, ZANTA MA et al.: A versatile vector for gene and oligonudeotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA (1995) 92(16)7297-7301.
55. BOLOGNA JC, DORN G, NATT F, WEILER J: Linear polyethylenimine as a tool for comparative studies of antisense and short double-stranded RNA oligonucleotides. Nucleosides Nucleotides Nucleic Acids (2003) 22(5-8):1729-1731.
56. TUSCHL T: Expanding small RNA interference. Nat. Biotechnol. (2002) 20(5):446-448.
57. BRUMMELKAMP TR, BERNARDS R, AGAMI R: A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 296(5567):550-553.
58. MIYAGISHI M, TAIRA K: U6 promoter driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nat. Biotechnol. (2002) 20(5):497-500.
59. PAUL CP, GOOD PD, WINER I, ENGELKE DR: Effective expression of small interfering RNA in human cells. Nat. Biotechnol. (2002) 20(5):505-508.
60. SCHERR M, BATTMER K, GANSER A, EDER M: Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. Cell Cycle (2003) 2(3):251-257.
61. FISH RJ, KRUITHOF EK: Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. BMC Mol. Biol. (2004) 5(1):9.
62. HACEIN-BEY-ABINA S, VON KALLE C, SCHMIDT M et al.: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 302(5644):415-419.
63. MARTINEZ J, TUSCHL T: RISC is a 5′ phosphomonoester-producing RNA endonuclease. Genes Dev. (2004) 18(9):975-980.
64. SAXENA S, JONSSON ZO, DUTTA A: Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J. Biol. Chem. (2003) 278(45):44312-44319.
65. JACKSON AL, BARTZ SR, SCHELTER J et al.: Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. (2003) 21(6):635-637.
66. BRIDGE AJ, PEBERNARD S, DUCRAUX A, NICOULAZ AL, IGGO R: Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. (2003) 34(3):263-264.
67. SLEDZ CA, HOLKO M, DE VEER MJ, SILVERMAN RH, WILLIAMS BR: Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. (2003) 5(9):834-839.
68. KIM DH, LONGO M, HAN Y et al.: Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol. (2004) 22(3):321-325.
69. KARIKO K, BHUYAN P, CAPODICI J, WEISSMAN D: Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J. Immunol. (2004) 172(11):6545-6549.
70. HOLEN T, AMARZGUIOUI M, WIIGER MT, BABAIE E, PRYDZ H: Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res. (2002) 30(8):1757-1766.
71. CHEN CZ, LI L, LODISH HF, BARTEL DP: MicroRNAs modulate hematopoietic lineage differentiation. Science (2004) 303(5654):83-86.
72. http://cgap.nci.nih.gov/Chromosomes/Mitelman The Cancer Genome Anatomy Project: Mitelman Database of Chromosome Aberrations in Cancer.